首页> 外文期刊>Haemophilia: the official journal of the World Federation of Hemophilia >Results of a Pivotal Clinical Trial Evaluating a Full-length Pegylated Recombinant Factor VIII (PEG-rFVIII) with Extended Half-life in Hemophilia A

【24h】

Results of a Pivotal Clinical Trial Evaluating a Full-length Pegylated Recombinant Factor VIII (PEG-rFVIII) with Extended Half-life in Hemophilia A

机译：一项重要的临床试验评估了全长的聚乙二醇化重组因子VIII（PEG-rFVIII），并延长了A型血友病患者的半衰期

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Haemophilia: the official journal of the World Federation of Hemophilia》 |2015年第3期|共1页
作者
Konkle B.; Stasyshn O.; Wynn T.; Manco-Johnson M.; Gruppo R.; Tran H.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类妇产科学;
关键词

相似文献

外文文献
中文文献
专利

1. Results of a Pivotal Clinical Trial Evaluating a Full-length Pegylated Recombinant Factor VIII (PEG-rFVIII) with Extended Half-life in Hemophilia A [J] . Konkle B., Stasyshn O., Wynn T., Haemophilia: the official journal of the World Federation of Hemophilia . 2015,第3期

机译：一项重要的临床试验评估了全长的聚乙二醇化重组因子VIII（PEG-rFVIII），并延长了A型血友病患者的半衰期
2. Efficacy and safety of full-length pegylated recombinant factor VIII with extended half-life in previously treated patients with hemophilia A: comparison of data between the general and Japanese study populations (vol 106, pg 704, 2017) [J] . Nogami Keiji, Shima Midori, Fukutake Katsuyuki, International journal of hematology . 2018,第1期

机译：全长聚乙二醇化重组因子VIII在先前治疗血友病患者中延长半衰期的疗效和安全性A：一般和日本研究人群数据的比较（Vol 106，PG 704,2017）
3. Efficacy and safety of pegylated full-length recombinant factor VIII with extended half-life for perioperative haemostasis in haemophilia A patients [J] . Brand B., Gruppo R., Wynn T. T., Haemophilia: the official journal of the World Federation of Hemophilia . 2016,第4期

机译：半衰期延长的聚乙二醇化全长重组凝血因子对A型血友病患者围手术期止血的疗效和安全性
4. Inactiwatlon of Animal Factor VIII by human Factor VIII Inhibitors: Inwestigation of Plasma from Patients with Inhibitors in congenital Hemophilia I and from Patients with acquired Hemophilia A [C] . V. Aumann, G. Lutze (Jr.), G. Lutze (Sen.), Hemophilie-Symposion . 2003

机译：人为因子VIII抑制剂的动物因子VIII的乙酰丁酮：先天性血友病药中抑制剂患者的血浆中的预防
5. Satisfaction, Adherence, and Recombinant Factor VIII Choice of Patients with Moderate to Severe Hemophilia A [D] . Strickland, Kimberly. 2020

机译：满意度，依从性和重组因素VIII患者中度至重度血友病的患者
6. Phase I study of BAY 94-9027 a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life in subjects with hemophilia A [O] . T E Coyle, M T Reding, J C Lin, -1

机译：BAY 94-9027 I期研究在患有血友病A的受试者中进行这是一种具有半衰期延长的PEG化B结构域缺失的重组因子VIII
7. Correction to: Efficacy and safety of full-length pegylated recombinant factor VIII with extended half-life in previously treated patients with hemophilia A: comparison of data between the general and Japanese study populations [O] . Keiji Nogami, Midori Shima, Katsuyuki Fukutake, 2017

机译：校正：全长聚乙二醇化重组因子VIII在先前治疗血友病患者中延长半衰期的疗效和安全性A：一般和日本研究人群之间的数据比较

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号